Mallinckrodt Pharmaceuticals plc has announced an expansion of commercial capabilities for the organization's hospital, and autoimmune and rare diseases, or ARD, businesses. To meet these needs, the company will amplify its focus on business strategy and portfolio development and intensify efforts to expand and deepen talent in the commercial organization. The business will create a new cohort of general business manager roles across the organization with four in key ARD therapeutic areas (Rheumatology, Neurology, Nephrology, and Pulmonology) and similar leadership roles in Mallinckrodt's Hospital and Office Brands franchises.

As the business continues efforts to build out its broader commercial organization, Hugh O'Neill, Senior vice president and President, Specialty Pharmaceuticals, will assume responsibility for all specialty pharmaceutical commercial operations, including the hospital organization which he currently oversees and, in the interim, the sales, support and service activities for the recently acquired ARD business. O'Neill will also continue to have responsibility for the company's broad market access activities. Phillips and O'Neil will continue to serve as members of Mallinckrodt's Executive Committee, and report directly to Trudeau. Both executives' appointments are effective January 7, 2015.